The CysLT1 receptor antagonist montelukast blocks bronchoconstriction induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015
Interaction between the Arg16 homozygous genotype, inhaled corticosteroids and long acting beta agonists for asthma exacerbations in children? Leukotriene receptor antagonists to the rescue? Source: Annual Congress 2013 –Asthma and lung development: from genes to environment Year: 2013
The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016
First line anti-inflammatory treatment for asthma: inhaled steroid or leukotriene antagonist? Source: Eur Respir J 2002; 20: Suppl. 38, 93s Year: 2002
Leukotriene C4 synthase polymorphism does not associate with clinical response to leukotriene receptor antagonists in persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002
The effects of a cysteinyl leukotriene receptor antagonist, pranlukast, on dendritic cell chemoattractants in the airways of subjects with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
Side effects of the leukotriene receptor antagonists in asthmatic children Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
Long-term treatment with a leukotriene antagonist Source: Eur Respir J 2004; 24: Suppl. 48, 126s Year: 2004
Pharmacological treatment of asthma today Source: Eur Respir J 2001; 18: 34S-40S Year: 2001
Anti-inflammatory effects of histamine H1 -receptor antagonist and leukotriene CysLT1 -receptor antagonist in patients with atopic asthma maintained on inhaled corticosteroids Source: Eur Respir J 2004; 24: Suppl. 48, 221s Year: 2004
Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004
Effects of a newly developed dual CysLT1 and CysLT2 receptor antagonist, ONO-RS-531, on antigen- and leukotriene D4 -induced contractions of isolated human bronchi Source: Eur Respir J 2005; 26: Suppl. 49, 214s Year: 2005
Alternative transcripts of cysteinyl leukotriene receptor 1 in patients with bronchial asthma Source: Annual Congress 2007 - Novel mediators of cellular pathology Year: 2007
Safety and toleration of pf-00610355, a novel inhaled long acting β2 adrenoreceptor agonist Source: Annual Congress 2009 - New bronchodilators Year: 2009
Study of improvement of exercise-indused bronchospasm by montelukast, a leukotriene antagonist Source: Eur Respir J 2004; 24: Suppl. 48, 502s Year: 2004
Leukotriene receptor antagonist (LTRA) montelukast for the treatment of acute bronchiolitis in infants Source: Eur Respir J 2004; 24: Suppl. 48, 504s Year: 2004
Effects of leukotriene receptor antagonists on airway mucus secretion Source: Eur Respir J 2001; 18: Suppl. 33, 245s Year: 2001
Real-life use and impact of inhaled steroids (ICS) and leukotriene receptor antagonists (LTRA) monotherapy in children with asthma Source: Annual Congress 2010 - Paediatric asthma treatment and monitoring Year: 2010
Effect of cysteinyl leukotriene receptor antagonist on airway wall remodeling Source: Eur Respir J 2002; 20: Suppl. 38, 304s Year: 2002
Factors influencing the relative effect of leukotriene receptor antagonists (LTRA) and inhaled corticosteroids (ICS) as monotherapy in persistent asthma: A systematic review Source: Annual Congress 2011 - Asthma management and response Year: 2011